Needham Maintains Buy on Stoke Therapeutics, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has maintained a 'Buy' rating on Stoke Therapeutics (NASDAQ:STOK) but lowered the price target from $25 to $14.

November 07, 2023 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Stoke Therapeutics but lowered the price target from $25 to $14.
The news is directly related to Stoke Therapeutics. While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential downside risk in the short term. However, the impact on the stock price is uncertain as the 'Buy' rating might still attract investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100